[Rational hypoglycemic therapy - nephro-diabetologic view].
Marcin Kosmalski1, Ilona Kurnatowska1
1Zakład Farmakologii Klinicznej, I Katedra Chorób Wewnętrznych Uniwersytetu Medycznego w Łodzi, Oddział Nefrologii, Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego w Łodzi.
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|September 22, 2018
Summary
Managing diabetes and chronic kidney disease requires careful selection of hypoglycemic drugs. This study analyzes new agents, their renal benefits, and risks across different kidney disease stages.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus causes chronic hyperglycemia, increasing risks of complications like diabetic kidney disease.
- Hyperglycemia-induced micro- and macroangiopathy can lead to end-stage renal disease, necessitating dialysis or transplantation.
- Kidney dysfunction in diabetic patients may stem from causes other than diabetes, requiring nephrological monitoring.
Purpose of the Study:
- To review current hypoglycemic therapy options for patients with varying stages of chronic kidney disease.
- To analyze the renal benefits and risks associated with different classes of hypoglycemic agents.
Main Methods:
- Literature review of current hypoglycemic agents and their use in chronic kidney disease.
- Analysis of studies examining the impact of specific hypoglycemic drug classes on renal function and outcomes.
Main Results:
- Newer hypoglycemic agents offer potential therapeutic benefits for diabetic patients with chronic kidney disease.
- Careful drug selection and dosage adjustment are crucial to minimize adverse effects and optimize renal protection.
- Individualized treatment strategies considering kidney function are essential for managing hyperglycemia and slowing disease progression.
Conclusions:
- Hypoglycemic therapy in diabetic patients with chronic kidney disease requires individualized approaches.
- Understanding the renal effects of different hypoglycemic agents is key to improving patient outcomes.
- Ongoing research into novel agents and treatment paradigms is vital for managing this complex patient population.
Related Concept Videos
01:24Rational Emotive Behavior Therapy
448
Cognitive-behavioral therapies (CBTs) are grounded in the belief that our thoughts profoundly influence our emotions and actions. Advocates of CBT emphasize three core assumptions: first, that cognitions are identifiable and measurable; second, that they are central to psychological functioning; and third, that irrational or maladaptive beliefs can be replaced with rational and adaptive ones. This transformative approach to therapy has paved the way for specific models such as Albert...
448
01:29Rationalizing Substitutions
60
Integrals involving non-rational functions are often difficult to evaluate using standard techniques, especially when radicals appear in the integrand. Rationalizing substitution provides a systematic method for simplifying such integrals by converting them into rational forms that are easier to handle.Consider a rod whose linear mass density depends on a constant linear density, a characteristic length, and the distance from the left end of the rod. Determining the total mass requires...
60
01:28Rational Expressions
401
Rational expressions are algebraic fractions in which both the numerator and the denominator are polynomials. These expressions follow the arithmetic rules of numerical fractions but require extra care due to the presence of variables. A fundamental part of working with rational expressions is identifying values that make the expression undefined, typically those that result in division by zero or undefined radicals.Determining the DomainThe domain of a rational expression includes all real...
401
01:06Oral Hypoglycemic Agents: Glinides
671
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
671
01:30Asymptotes in Rational Functions
254
A rational function is defined as the quotient of two polynomials: where Q(x)≠0, These functions often exhibit asymptotes, which are the lines that the graph approaches but never touches. These asymptotes are classified based on how the function behaves near specific values of the input.Vertical asymptotes occur where the denominator is zero, and the numerator is not, causing the function to be undefined. These are found by solving Q(x)=0. For example: has a vertical...
254
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.1K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.1K